Close
UCL spinout tackling eye disease announces £57m launch
12 July 2023
Tenpoint Therapeutics, which spun out of UCL in 2021, has announced its launch to address degenerative eye diseases.
The biotechnology company uses pioneering cell engineering to replace damaged cells in the eye to tackle age-related or inherited sight loss. The technology could potentially restore sight to millions affected.
The experts at Tenpoint Therapeutics, from the UCL Institute of Ophthalmology, Moorfields Eye Hospital, Institut de la Vision in Paris and the University of Washington in the US, are the first to combine different types of cell-based therapeutics and enable treatments that are tailored to the nature of individual cases, replacing cells in the eye that have been damaged by age-related or inherited disease.